August 2025

Precision oncology has shifted, yet pharmacists’ roles remain underutilized.

Pharmacists optimize biosimilar and 505(b)(2) use through collaboration, education, and integration.

Oncology pharmacists can lead value-based care integration under EOM with data-driven strategies.

BV-R2 combination shows survival benefit across high-risk subgroups.

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.

August marks a pivotal time for oncology pharmacy, blending transitions, celebrations, and new beginnings as professionals prepare for the upcoming season.